Form 4: AN2 Therapeutics CSO Sells Shares for Tax Obligations

AN2 Therapeutics' Chief Strategy Officer, Stephen David Prior, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, Inc. (ANTX), sold 3,604 shares of common stock on January 5, 2026, at $1.003 per share.
• An additional 2,858 shares of common stock were sold on January 6, 2026, at $1.012 per share.
• These sales were conducted to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2026.
• Following these transactions, Stephen David Prior beneficially owns 59,086 shares of common stock.
• Remaining RSU holdings include 10,125 RSUs vesting annually over four years from November 4, 2024; 17,500 RSUs vesting through December 31, 2024, with 1/3 vesting on January 1, 2025, and the remainder on January 1, 2026; and 28,000 RSUs vesting annually over four years from January 1, 2025.
• All RSU vesting is contingent upon continued service to the company.

Sentiment

Score: 6

Explanation: The filing details a routine executive stock sale for tax purposes, which is a neutral event. The continued significant RSU holdings and future vesting schedules indicate ongoing executive alignment and retention, which is a positive signal.

Positives

• The Chief Strategy Officer continues to hold a significant number of shares and unvested Restricted Stock Units (RSUs), indicating ongoing alignment with shareholder interests.
• The vesting schedules for RSUs extend into future years (e.g., from November 4, 2024, and January 1, 2025), suggesting continued commitment and retention of key management.

Negatives

• The sale of 6,462 shares of common stock by a key executive, even for tax purposes, reduces their direct equity holding.

Risks

• The vesting of Restricted Stock Units (RSUs) is contingent upon the Reporting Person continuing to provide services to the Company as an employee, consultant, or director, posing a risk if the executive's service terminates.

Future Outlook

The Chief Strategy Officer has significant unvested Restricted Stock Units (RSUs) with vesting schedules extending through January 1, 2026, and beyond, contingent on continued service. This indicates a long-term incentive structure designed to retain the executive.

Industry Context

This Form 4 filing reflects a routine executive compensation event common across publicly traded companies, particularly in the biotechnology or pharmaceutical sector where AN2 Therapeutics operates. The sale of shares to cover tax obligations upon RSU vesting is a standard practice and does not inherently signal a change in company fundamentals or executive sentiment beyond the mechanics of compensation.

Comparison to Industry Standards

• The practice of executives selling shares to cover tax withholding obligations upon RSU vesting is a common and standard practice across all industries, including biotechnology.
• Many companies, such as Pfizer (PFE), Johnson & Johnson (JNJ), and Moderna (MRNA), have similar executive compensation structures involving RSUs, where executives routinely sell a portion of vested shares to satisfy statutory tax requirements.
• The vesting schedules, extending over multiple years, are typical for executive retention programs, aligning the executive's long-term interests with the company's performance, comparable to practices at companies like Gilead Sciences (GILD) or Amgen (AMGN).

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a routine event and generally has minimal direct impact on share price or company operations. The executive's continued RSU holdings suggest ongoing commitment.
• Employees: The executive's continued service and RSU vesting schedule indicate stability in leadership.

Next Steps

• Continued vesting of 10,125 RSUs annually over four years from November 4, 2024.
• Continued vesting of 17,500 RSUs through December 31, 2024, with 1/3 vesting on January 1, 2025, and the remainder on January 1, 2026.
• Continued vesting of 28,000 RSUs annually over four years from January 1, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine executive transaction (sale of shares for tax withholding upon RSU vesting) and provides insight into the executive's compensation structure and future equity incentives. It does not contain information that would fundamentally alter the investment thesis for AN2 Therapeutics. The executive's continued significant RSU holdings suggest ongoing alignment with company performance. Therefore, a "hold" recommendation is appropriate as this filing alone does not present new information warranting a change in investment strategy.

Keywords

AN2 Therapeutics, ANTX, Form 4, insider trading, stock sale, RSU, restricted stock units, executive compensation, Stephen David Prior, Chief Strategy Officer, tax withholding, beneficial ownership